OBJECTIVES: Abiraterone acetate and enzalutamide, novel anti-androgen therapies with distinct modes of action for the treatment of metastatic castration-resistant prostate cancer (mCRPC), are approved in both the pre-chemotherapy and post-chemotherapy settings. These anti-androgen therapies have significantly improved outcomes among mCRPC patients. However, to date there is little published evidence regarding patients’ real-world experience of these therapies in both the pre-chemotherapy or post-chemotherapy settings, particularly in terms of health-related quality of life (HRQoL) and treatment satisfaction. METHODS: Qualitative face-to-face interviews were conducted with mCRPC patients (n=38) and carers (n=12) to obtain in-depth data concerning the patient experience with novel anti-androgen therapy.  This included patients with experience of abiraterone acetate or enzalutamide in either the pre-chemotherapy or post-chemotherapy setting in France, Germany and the UK. Findings from this study have been used to inform the design of a larger quantitative, multinational online survey to further explore and quantify HRQoL and treatment satisfaction among mCRPC patients receiving anti-androgen therapy. RESULTS: Patients generally had high expectations at initiation of therapy with a primary emphasis on reduction in prostate-specific antigen levels and improvements in HRQoL. Patients and carers reported that experiences on treatment had met or exceeded expectations. Administration procedures appeared to be of limited concern for patients and only mentioned by patients when prompted by directive questions. In particular, the need to take abiraterone acetate on an empty stomach was not deemed problematicSome differences in the patient experience (e.g. side effects) and HRQoL of patients receiving abiraterone acetate and enzalutamide were noted and warrant further exploration. CONCLUSIONS: Patients and carers reported largely positive experiences with novel anti-androgen therapies for the treatment of mCRPC. Potential differences between regimens in terms of treatment satisfaction and HRQoL are currently being explored in a larger quantitative online study.